Celltrion secures approval for new drug product plant in Songdo
The new facility, permitted by the Incheon Free Economic Zone Authority, will be located near the company's existing Plant 1 and have an annual production capacity of around 8 million liquid vials.
Celltrion plans to complete construction in the first half of 2026 to begin full-scale commercial production in 2027. The plant will manufacture existing biosimilar products such as Truxima and Vegzelma, along with newly approved liquid vial treatments like Idencelt, Stekyma and Aptozuma.
Pharmaceutical products are generally categorized into drug substances (DS), produced through processes such as cell culture and purification, and drug products, the finished form of the drug formulated for patient administration.
With the expansion of its DP manufacturing capacity, the company anticipates a 30 percent reduction in production costs per product compared to current contract manufacturing organization expenses, strengthening its competitiveness in international bidding markets.
The new DP plant will feature isolators to prevent exposure to hazardous substances, reducing contamination risks while enhancing operational efficiency through advanced manufacturing equipment and process automation.
By integrating the new facility with the existing DP production line at Plant 2, the company aims to shorten product shipment timelines, improve workforce efficiency and enhance overall production capabilities.
The increased in-house DP manufacturing capacity will also allow greater flexibility in global supply strategies. With expanded options for DS and DP supply, Celltrion can better adapt to country-specific market conditions and export requirements.
Meanwhile, the company plans to adopt a flexible production strategy in the US by leveraging local CMO partnerships to mitigate potential tariff risks. This two-track approach is expected to enhance market responsiveness in line with global economic conditions.
To meet the growing global demand for pharmaceuticals and expand its product portfolio, Celltrion has been strengthening its production capabilities.
The company has secured a total DS production capacity of 250,000 liters, consisting of its 100,000-liter Plant 1, 90,000-liter Plant 2 and the recently operational 60,000-liter Plant 3.
For DP production, the company currently manufactures 4 million liquid vials annually at Plant 2. With the additional 8 million vials from the new facility, Celltrion's total annual DP production capacity will increase to 12 million vials.
"With the DP plant expansion, we can proactively respond to rising global demand and new product launches, ensuring a stable supply of high-quality pharmaceuticals," a Celltrion official said. "By strengthening our production capacity and cost competitiveness, we aim to accelerate global market expansion and drive company growth."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
12-08-2025
- Korea Herald
Celltrion expands presence in Italy with autoimmune, anticancer drugs
Korean biopharma scores seven contracts in first half of 2025 in major European market Celltrion has won bids to supply its autoimmune drug Steqeyma in seven states in Italy in the first half of this year to expand its presence in the country, the Korean biopharmaceutical company said Tuesday. According to Celltrion, it recently won the bids for autoimmune medicine in Veneto, Trentino-Alto Adige and Sardinia. The drug maker said it plans to supply Steqeyma to these regions through May. Celltrion pointed out that the drug rapidly secured contracts after launching in Italy in January. Remsima, Celltrion's flagship autoimmune drug, also continues to secure orders in Italy as it won a bid in the state of Umbria, while Remsima SC was able to renew a contract with Puglia. According to Celltrion, Remsima SC is being sold in all 20 states in Italy. Medicine market analyst IQVIA estimates that Remsima and Remsima SC combined for 66 percent of the Italian autoimmune drug market in the first quarter. Celltrion's anticancer drugs Truxima and Vegzelma won the bids in the states of Lazio and Umbria, respectively, earlier in the year, taking up 29 percent and 30 percent of the market. The company said it expects to keep supplying anticancer drugs in Italy as more bids are scheduled in the second half of the year. 'Based on high trust from major stakeholders in Italy's medical industry, a key pharmaceutical market in Europe, Celltrion's autoimmune treatments and anticancer drugs are expanding influence by logging a series of orders,' said Yoo Won-sik, general manager of Celltrion's Italian office. 'We will continue to launch new products and score more orders in the second half to expand the prescription of our products and keep up the growth of performance.'
Korea Herald
06-08-2025
- Korea Herald
Celltrion's Q2 net falls 19.3% on provisions
Celltrion, a major South Korean biopharmaceutical company, said Wednesday its second-quarter net profit fell 19.3 percent from a year earlier due to provisions related to ongoing legal disputes. For the three months ended June 30, net profit declined to 63.3 billion won ($45.6 million) from 78.4 billion won in the same period last year, the company said in a regulatory filing. "We set aside provisions in preparation for potential compensation related to ongoing legal disputes. These provisions impacted our quarterly bottom line," a company spokesperson said, without elaborating. Operating profit more than tripled to 242.5 billion won from 72.4 billion won, while sales rose 9.9 percent to 961.5 billion won from 874.7 billion won. The company said increased global sales of its flagship biosimilars, including Remsima SC, Yuflyma and Vegzelma, supported quarterly earnings. These high-margin products accounted for 53 percent of total sales in the second quarter. In the first half of the year, net income surged 73 percent to 171.6 billion won from 99.2 billion won a year earlier. Celltrion expects strong earnings to continue in the second half, as it plans to gradually launch five new biosimilars -- Omlyclo, Avtozma, Eydenzelt, Stoboclo and Osenvelt -- in global markets later this year. The company aims to achieve 5 trillion won in annual sales this year, up 40 percent from a record 3.56 trillion won last year. Celltrion has significantly expanded its global biosimilar portfolio, with the number of approved products rising from six to 11. It plans to commercialize 22 biosimilar products by 2030, when the global market is projected to grow to 261 trillion won from 138 trillion won this year. (Yonhap)
Korea Herald
29-07-2025
- Korea Herald
Celltrion nears US plant deal to go ‘made in USA'
Biosimilar giant to invest W700b in new US plant, double spending for expansion, chief says Celltrion Group Chairman and founder Seo Jung-jin said Tuesday that the company is preparing for new US tariffs by moving closer to acquiring a biologics manufacturing facility in the United States -- a move that would give Celltrion greater access to a market Seo framed as 'indispensable.' According to a regulatory filing Tuesday, Celltrion has been named the preferred bidder for a large-scale biologics manufacturing facility in the US, a cGMP or "current Good Manufacturing Practice" drug substance site located within a major pharmaceutical hub. The seller and deal value remain under wraps pending final agreement, expected in early October. 'The US is simply too big a market to walk away from, and we're aiming to eliminate uncertainty in our US sales,' said Seo during a livestreamed press conference Tuesday. 'If the US government wants drugs to be made in the US, then our plan is to produce them there accordingly.' Celltrion currently sells 11 biosimilars in the US, with plans to expand its portfolio to 22 by 2030 and 41 by 2033. It is also conducting Phase 1 trials for four novel drug candidates this year, with the goal of submitting investigational new drug applications for a total of 13 by 2028. Once due diligence is complete and the acquisition finalized, Celltrion is set to largely eliminate tariff-related risks for its pharmaceutical products in the US, backed by two years' worth of US-bound inventory and expanded contracts with local contract manufacturers. The deal includes a contract manufacturing agreement covering 50 percent of the facility's capacity, granting exclusive rights to produce the seller's biologics for five years. 'That means we won't be operating at a loss from day one,' Seo continued. 'The other half will be used to manufacture our own products for the US market.' He added that the potential acquisition brings a team of development personnel, which would complement Celltrion's existing research capabilities. Celltrion is also considering follow-up investments depending on how US tariff policies take shape. While the total cost of acquiring and operating the facility is expected to reach roughly 700 billion won ($503 million), Seo said a minor expansion could require an additional 300 billion won. 'In the case of a large-scale buildout, we estimate up to 700 billion won in extra investment,' he said. The expanded facility would be up to 1.5 times the size of Celltrion's second plant in Songdo, Incheon, he added. While highlighting the cost and time advantages of acquiring an existing facility, Seo noted that competition would likely remain limited due to high capital requirements and long lead times for local production. 'We believe US drug prices are likely to rise, and for companies that complete local production early, this could be a major opportunity,' he noted. As for the sales outlook, Seo said the company is on track to deliver 4.5 to 4.6 trillion won in sales this year -- of Celltrion's five trillion won full-year goal -- with operating profit expected to reach about 1.5 trillion won. In the second quarter, Celltrion posted record revenue and operating profit, with revenue rising 9.9 percent from a year earlier to 961.5 billion won and operating profit jumping 234.5 percent to 242.5 billion won.
